

Editorial

The year of 2006 has been for the *European Journal of Pharmaceutics and Biopharmaceutics* undoubtedly the most successful in its recent history. The impact factor increased to 2.525 according to ISI (Institute of Scientific Information) and EJPB is by this ranking one of the leading journals in the area of pharmaceutics and biopharmaceutics.

To point out some major changes for the last year, EJPB joined forces with the European Association of Pharmaceutical Biotechnology (EAPB), and followed up the section dedicated to Pharmaceutical Biotechnology. The section has experienced an increasing flow of manuscripts since its inception. Over the next years, we will work to increase publication in this area of pharmaceutical research of increasing importance. While soliciting manuscripts dealing with all aspects of pharmaceutical biotechnology, including discovery, developmental and regulatory aspects, we are at the same time continuing to identify experts in the field who will volunteer as reviewers. To assist us in the process of enhancing our reviewer database, we are asking submitting authors to identify experts in the field who may serve as reviewers. This will help us tremendously to both smoothen and speed up the review process.

To strengthen the journal's international orientation Prof. Jean-Christophe Leroux from the Faculty of Pharmacy at the University of Montreal, Canada, was appointed as a new acting editor.

Also in 2006, EJPB changed to the Elsevier Electronic Submission System (EES), for which we got "in majority" very positive feedback from our authors and reviewers. With this change the number of manuscripts we received has increased tremendously by more than 100%. The current rejection rate is above 60% and it is anticipated that this number will further increase in 2007. Please note that EJPB will publish only innovative papers of highest quality and of high scientific impact.

For the year 2007 we plan some improvements as well as a few minor changes.

In the world of electronic exchanges of scientific publications EJPB has abandoned the old concept of regional responsible editors. This means that all our editors will take care of papers from all over the world. For the printed issues, the following changes will take place. The well regarded "thesis section", in which we announce recently published PhD work will from now on only be available in the electronic version, and will be accessible online via the journal's website or ScienceDirect. The "instructions for authors" will be published only once at the beginning of each volume, they are also available online.

Furthermore we plan to introduce a new section called "State of the art in ...". These articles will be written by eminent scientists, to publish a short analysis of a topic in pharmaceutics and biopharmaceutics, and pharmaceutical biotechnology in a tutorial manner, including data and a short selection of relevant references. The new "State of the art in ..." articles will be seen as complementary to the classical Review articles.

The Editorial Team, in the USA, Canada, Europe, and Japan are looking forward to the year 2007 for your and with your support.

Dr. M. Möller
(Associate Editor)

Prof. G. Borchard
(Section Editor Biotechnology)

Prof. R. Gurny
(Editor-in-Chief)